Microglia/Macrophages and Neuroprotection in Glaucoma
About the Research Project
Program
Award Type
Standard
Award Amount
$90,000
Active Dates
April 01, 2005 - March 31, 2007
Grant ID
G2005001
Summary
Glaucoma is a chronic disease in which the neurons, called retinal ganglion cells, undergo degeneration. Another trait of developing glaucoma is an increase of pressure within the eyes. Recently, a novel approach was proposed to utilize our body immunity to protect neurons in the eyes. Dr. Chang’s study aims to define which factors or what conditions for the activation of innate immune cells can lead these cells to elicit protective effects. He will also study how a Chinese medicine, Chinese Wolfberry, exhibits protective effects to neurons in the eyes via mild activation of innate immune cells. Knowledge of how body immunity exerts protective effects to neurons in the eyes will hopefully pave a new road for therapeutic intervention against loss of vision in glaucoma.
Related Grants
National Glaucoma Research
Exploring Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Glaucoma
Active Dates
July 01, 2026 - June 30, 2028
Principal Investigator
Qi Cui, MD, PhD
Current Organization
University of Pennsylvania, Perelman School of Medicine
Exploring Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Glaucoma
Active Dates
July 01, 2026 - June 30, 2028
Principal Investigator
Qi Cui, MD, PhD
Current Organization
University of Pennsylvania, Perelman School of Medicine
National Glaucoma Research
Measuring the Effects of Visual Stimuli on Retinal Blood Vessels and Flow
Active Dates
July 01, 2026 - June 30, 2028
Principal Investigator
Stuart Gardiner, PhD
Current Organization
Good Samaritan Foundation, Legacy Health System
Measuring the Effects of Visual Stimuli on Retinal Blood Vessels and Flow
Active Dates
July 01, 2026 - June 30, 2028
Principal Investigator
Stuart Gardiner, PhD
Current Organization
Good Samaritan Foundation, Legacy Health System
National Glaucoma Research
Developing New Drugs for Glaucoma
Active Dates
January 01, 2026 - December 31, 2027
Principal Investigator
Pete Williams, PhD
Current Organization
Karolinska Institutet
Developing New Drugs for Glaucoma
Active Dates
January 01, 2026 - December 31, 2027
Principal Investigator
Pete Williams, PhD
Current Organization
Karolinska Institutet